It is true that the President’s Emergency Plan for AIDS Relief, PEPFAR, remains the most effective large-scale public-health intervention any government has ever fielded—a program that saved roughly 26 million lives since George W. Bush launched it in 2003. Before PEPFAR, hospitals across southern Africa were burial grounds with beds, and the air in Johannesburg’s townships carried what activist Lucky Mazibuko calls “the stench of death.” The drug supply lines turned a guaranteed early death sentence into a manageable chronic condition, and for two decades the coalition that kept those lines funded was broad enough to survive six Congresses and four presidencies. The trouble is that the administrative drift the administration is citing as justification is the cover story for a different transaction. The cuts to USAID and the freezing of HIV-prevention programs across South Africa and Mozambique are not an exercise in fiscal discipline; they are an unpriced clearance sale of established public-health infrastructure, where the physical clinics, the cold-chain logistics, and the patient registries are being stripped to extract value for private mineral concessions and surveillance datasets.

As this publication documented last week, the administration has been negotiating mineral access and data-sharing demands in exchange for the remnants of health aid. The mechanism is brutally simple but requires reading the funding freeze not as a cancellation, but as an asset-stripping maneuver. PEPFAR is not merely a bank account transferred from one government ledger to another; it is a distributed system. It relies on a network of localized clinics—like the WITS RHI clinic in Hillbrow or the Unjani Clinic in Soweto—that handle patient onboarding, viral-load testing, and consistent antiretroviral dispensing. The CATALYST study, which tracked prevention outcomes, was terminated in January. The WITS RHI Women’s Health Clinic in Hillbrow is padlocked. Health workers across South Africa and Mozambique are forgoing full pay to keep enough trust in their communities that the patients the United States abandoned will still come in for a viral-load test. None of this is happening because the effectiveness of antiretroviral therapy suddenly became unclear; it is happening because the administration has decided that the fear of a clinic closure is worth more as a negotiating position than the clinic itself was worth as a functioning node in a public-health network.

In the parlance of secure systems architecture, the local clinic acts as a trusted third party that verifies identity and distributes a life-critical payload. When the funding that maintains the clinic evaporates, the administrator does not just remove the money; they destroy the trust anchor. Patients who rely on a consistent monthly supply of medication will default when the supply chain breaks. When viral-load monitoring halts and pre-exposure prophylaxis supply dries up—as the abrupt cancellation of the CATALYST study demonstrates—viral suppression collapses. Patients who miss doses rebound to transmission-level viral loads, and the epidemic does not pause politely. It climbs back up the privilege gradient. The first to fall are the marginalized populations, the communities in Hillbrow or the mining belts that do not have the financial buffer to weather a supply-chain rupture.

The playbook is older than the phrase “mRNA.” The sequence—acquire a going concern that people cannot walk away from, run it down while extracting whatever surplus can be extracted, then discard it—is the sequence that hollowed out Canadian heavy industry after the 1995 free-trade realignment, and it is the same sequence now being applied to the institutions that have kept sub-Saharan Africa’s HIV epidemic from returning to its pre-PEPFAR death rate. Anyone who watched what happened on the prairies when a corporate buyer acquired a mill and immediately began liquidating the maintenance budget recognizes the cadence: extract the surplus, starve the upkeep, sell the machinery, and walk away when the foundation cracks. The only difference in the global-health context is that the “machinery” being liquidated includes the epidemiological barrier that kept drug-resistant strains of HIV from re-establishing across the southern African continent. In both cases the surplus flows to the operator, and in both cases the people who built the value are told, after the fact, that they should have seen the restructuring coming.

The administration is not cutting programs because they failed. It is cutting them because they worked—because the dependency they created is now a pressure point, and the pressure is being applied to obtain mining rights for cobalt and copper that the global battery industry’s margins cannot afford to do without. The document that would make the pattern legible is the administration’s own negotiation record, but that record is not being published. What is published is a growing ledger of closed clinics and paused trials, and the NPR reporting from Soweto that catches, in the voices of the clinicians who are being told to stop, a sound that was supposed to have been silenced by the arrival of cheap generic ARVs: the sound of a supply chain that was reliable becoming unreliable on purpose.

The State Department’s own 26-million-lives-saved figure was never a ceiling; it was a rolling count produced by a reporting apparatus that itself required funding—the same apparatus that ran the terminated CATALYST study and staffed the now-padlocked clinics. That apparatus is being dismantled, so the eventual mortality accounting will be done by external epidemiologists years from now, when the attribution gap will be wide enough to argue about. The mine contracts, by contrast, will be signed, notarized, and binding before the end of the fiscal year. A contract is easier to count than a body, and this administration has chosen which one it prefers to put on the ledger.

The remedy for the hollowing-out of the global health infrastructure is not charity; it is the ring-fencing of public health supply chains from geopolitical extraction. Antiretroviral drug patents should be overridden via the WTO’s TRIPS flexibilities when state-backed aid programs are frozen, and international health funding must be anchored to the WHO International Health Regulations framework, converting bilateral health obligations into binding treaties that cannot be unilaterally suspended by executive decree. You do not turn off the air traffic control system because a new administration dislikes the previous one’s flight paths. The Global Fund’s interruption-of-service reporting window is open now for documenting the collapse of these clinics; the paperwork is tedious, but standardized indicator reports are the only thing the bureaucrats who dismantle these programs will ever read. The deadline is approaching. The work is to be done.